The abstract is read at the publisher; the summary is JClub's.
VRAC-mediated D-2HG efflux via SWELL1 (LRRC8A)/LRRC8C is a principal release route in IDH-mutant glioma, and VRAC loss reverses immunosuppression in orthotopic mice.
- Why it matters: Tumor-derived D-2HG suppresses immunity and shapes an immune-cold TME, but how D-2HG exits IDH-mutant cells was unclear, limiting therapeutic targeting.
- What they did: The study identified SWELL1 as an essential VRAC subunit for D-2HG efflux, then tested SWELL1 deletion and dicumarol VRAC inhibition in an orthotopic mouse model and assessed human IDH-mutant lower-grade gliomas.
- The result: SWELL1/VRAC loss reduced D-2HG release, reversed immunosuppression, and caused intracellular D-2HG accumulation that limited proliferation via epigenetic remodeling and mitochondrial stress; dicumarol suppressed growth, boosted intratumoral T cell activation, synergized with immune checkpoint blockade, and prolonged survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.